XML 42 R35.htm IDEA: XBRL DOCUMENT v3.25.2
Fair Value - Additional Information (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
May 08, 2025
USD ($)
$ / shares
Sep. 30, 2024
USD ($)
Jul. 31, 2023
USD ($)
Installment
Apr. 07, 2022
Oct. 31, 2024
USD ($)
Jul. 31, 2024
USD ($)
Apr. 30, 2024
USD ($)
Installment
Apr. 30, 2022
USD ($)
Installment
Jan. 31, 2016
USD ($)
shares
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2018
USD ($)
Installment
shares
Feb. 28, 2025
$ / shares
Mar. 31, 2024
$ / shares
shares
Dec. 15, 2023
USD ($)
Nov. 21, 2022
shares
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                    
Amount withdrawn                   $ 50,016   $ 50,016            
Change in fair value of warrant liability $ 200                 (98)   280            
Loss on debt extinguishment                     $ (248)   $ (248)          
IPO                                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                    
Warrant, exercise price | $ / shares                               $ 4.46    
2018 Notes | Series G Preferred Stock                                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                    
Warrant issued to purchase shares | shares                               613,333    
Warrant, exercise price | $ / shares                               $ 0.75    
Tranche B Loan | Second Amendment                                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                    
Amount withdrawn                                 $ 10,000  
Contingent Consideration                                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                    
Interest expense due to passage of time and fixed payment schedule                     200   900          
Loss on debt extinguishment                     200              
Contingent Consideration | Third Amendment to APA Agreement                                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                    
Milestone payment           $ 8,400                        
Warrant Liabilities                                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                    
Warrant issued to purchase shares | shares                                   5,000,000
Change in fair value of warrant liability                   100 0 (300) 0          
Warrant Liabilities | Tranche C Loan                                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                    
Warrant, exercise price | $ / shares $ 0.4191                           $ 0.793      
Amount withdrawn $ 10,000                                  
Contingent Value Rights | Series F Preferred Stock                                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                    
Change in fair value of warrant liability                   $ 0 $ 0 $ 0 $ 0          
Percentage of net proceeds                 15.00%                  
Contingent Value Rights | Series F Preferred Stock | Ficlatuzumab                                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                    
Contingent value rights interest rate                 0.00375%                  
Shares issued | shares                 3,999                  
Drug interest rate percentage                 15.00%                  
Contingent value rights                 $ 500                  
Integrated Diagnostics, Inc                                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                    
Exit fee payment   $ 6,100                                
Integrated Diagnostics, Inc | Contingent Consideration                                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                    
Business acquisition description                       required additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month            
Business acquisition contingent consideration gross margin target                           $ 2,000        
Business acquisition contingent consideration gross margin target period                           7 years        
Integrated Diagnostics, Inc | Contingent Consideration | Third Amendment to APA Agreement                                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                    
Contingent consideration number of installments | Installment     3       1 5                    
Milestone payment     $ 3,000       $ 5,000 $ 2,000                    
Percentage of interest on installment payments       10.00%                            
Exit fee payment         $ 6,100                          
Integrated Diagnostics, Inc | Common Stock | Contingent Consideration                                    
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                                    
Business acquisition description                       If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.            
Contingent consideration shares | shares                           2,520,108        
Contingent consideration number of installments | Installment                           8        
Contingent consideration arrangements, common shares, redemption amount                       $ 4,600   $ 37,000        
Repayments of debt                       9,300            
Business combination contingent consideration final payment                       $ 37,000            
Contingent consideration cash payment                           $ 37,000        
Investment, Type [Extensible Enumeration]                           Repurchase [Member]